💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Purdue Pharma bankruptcy judge to rule Friday on opioid settlement

Published 08/25/2021, 04:03 PM
Updated 08/25/2021, 06:25 PM
© Reuters. FILE PHOTO: A pharmacist holds a bottle OxyContin made by Purdue Pharma, at a pharmacy in Provo, Utah, U.S., May 9, 2019.  REUTERS/George Frey/File Photo

By Maria Chutchian

(Reuters) -A U.S. judge in the Purdue Pharma bankruptcy case expects to rule on Friday on the OxyContin maker's request to approve its settlement of opioid-related litigation.

During a hearing on Wednesday, U.S. Bankruptcy Judge Robert Drain in White Plains, New York, said he plans to rule at the end of the week. A trial over the plan and settlement began on Aug. 12.

The deal, which Purdue says is worth more than $10 billion, has widespread support but is still opposed by nine U.S. states. Members of the Sackler family who own the company have said they will contribute about $4.5 billion in exchange for legal protections against opioid-related litigation.

© Reuters. FILE PHOTO: A pharmacist holds a bottle OxyContin made by Purdue Pharma, at a pharmacy in Provo, Utah, U.S., May 9, 2019.  REUTERS/George Frey/File Photo

Drain stated at the conclusion of Wednesday's hearing that Purdue, the Sacklers and the opposing states should continue efforts to reach a deal before Friday.

"I would encourage you ... to continue that work," he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.